title: Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer-preliminary results.
abstract: OBJECTIVE
  To evaluate the feasibility of dose escalation in a multi-institutional study in prostate cancer patients.
  
  
  METHODS
  Between October 1995 and October 1998, 164 patients with localized adenocarcinoma of the prostate were treated with 3-dimensional conformal radiotherapy at one of five French institutions. The dose of radiation was escalated from 66 to 80 Gy (ICRU point). The maximum dose to the rectal wall was limited to 75 Gy.
  
  
  RESULTS
  Results were compared in two groups, one (group 1) receiving the standard dose (n = 46 patients; 66 to 70 Gy) and the other (group 2) receiving the escalated dose (n = 118 patients; 74 to 80 Gy). There was no difference in the characteristics of patients between the two groups. The mean follow-up time was 32 months in group 1 and 17.5 months in group 2. No statistical difference between the two groups was observed in the incidence of late gastrointestinal and urinary toxicities. The probability of achieving a posttreatment prostate-specific antigen nadir of </=1 ng/mL in the 120 patients who did not receive neoadjuvant androgen-deprivation therapy was significantly higher in the dose-escalation group and was directly related to the dose of radiation given.
  
  
  CONCLUSIONS
  This multi-institutional study demonstrated the feasibility of escalating the dose of radiation to 80 Gy in prostate cancer patients.
authors.affiliation: Centre AlexisVautrin, Nancy, France. p.bey@nancy.fnc1cc.fr
authors.forename: P
authors.initials: P
authors.lastname: Bey
authors.forename: C
authors.initials: C
authors.lastname: Carrie
authors.forename: V
authors.initials: V
authors.lastname: Beckendorf
authors.forename: C
authors.initials: C
authors.lastname: Ginestet
authors.forename: P
authors.initials: P
authors.lastname: Aletti
authors.forename: G
authors.initials: G
authors.lastname: Madelis
authors.forename: E
authors.initials: E
authors.lastname: Luporsi
authors.forename: P
authors.initials: P
authors.lastname: Pommier
authors.forename: D
authors.initials: D
authors.lastname: Cowen
authors.forename: L
authors.initials: L
authors.lastname: Gonzague-Casabianca
authors.forename: M
authors.initials: M
authors.lastname: Simonian-Sauve
authors.forename: P
authors.initials: P
authors.lastname: Maingon
authors.forename: S
authors.initials: S
authors.lastname: Naudy
authors.forename: J
authors.initials: J
authors.lastname: Lagrange
authors.forename: S
authors.initials: S
authors.lastname: Marcie
mesh_terms: D000230:Adenocarcinoma / Q000532:radiotherapy*; D000368:Aged; D005240:Feasibility Studies; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000209:etiology; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal / Q000379:methods*
chemical_list: D017430:Prostate-Specific Antigen